Low-dose growth hormone administration mobilizes endothelial progenitor cells in healthy adults

Growth Hormone and IGF Research

Volumn 18, Issue 3, 2008, Pages 253-263

  Devin, Jessica K ^a   Vaughan, Douglas E ^b   Blevins Jr , Lewis S ^c   Chen, Qingxia ^b   Covington, Joseph ^b   Verity, Denise K ^b   Young, Pampee P ^b,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Aging; Angiogenesis; Endothelial function; Endothelial progenitor cells; Growth hormone; Insulin like growth factor 1

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; GENOTROPIN MINIQUICK; HUMAN GROWTH HORMONE; NITRIC OXIDE; NITRITE; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CELL COUNT; CLINICAL TRIAL; COLONY FORMING UNIT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE TITRATION; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEM CELL MOBILIZATION;

ADULT; AGED; CELL MOVEMENT; CELLS, CULTURED; DRUG TOXICITY; ENDOTHELIAL CELLS; FEMALE; HEALTH; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; STEM CELLS;

EID: 41649114350     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2007.11.001     Document Type: Article

References (41)

1. Urbich C., and Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. 95 (2004) 343-353
2. Schmidt-Lucke C., Rossig L., Fichtlscherer S., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111 (2005) 2981-2987
3. Fadini G.P., Coracina A., Baesso I., et al. Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Stroke 37 (2006) 2277-2282
4. Chironi G., Walch L., Pernollet M.G., et al. Decreased number of circulating CD34+KDR+ cells in asymptomatic subjects with preclinical atherosclerosis. Atherosclerosis 191 (2007) 115-120
5. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. New Engl. J. Med. 353 (2005) 999-1007
6. Aicher A., Heeschen C., Mildner-Rihm C., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9 (2003) 1370-1376
7. Iwakura A., Luedemann C., Shastry S., et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 108 (2003) 3115-3121
8. Laufs U., Werner N., Link A., et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109 (2004) 220-226
9. Llevadot J., Murasawa S., Kureishi Y., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 108 (2001) 399-405
10. Vasa M., Fichtlscherer S., Adler K., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
11. Werner N., and Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy?. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 257-266
12. Hoetzer G.L., Van Guilder G.P., Irmiger H.M., Keith R.S., Stauffer B.L., and Desouza C.A. Aging, exercise, and endothelial progenitor cell clonogenic and migratory capacity in men. J. Appl. Physiol. 102 (2007) 847-852
13. Khan A.S., Sane D.C., Wannenburg T., and Sonntag W.E. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc. Res. 54 (2002) 25-35
14. Boger R.H. Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans. J. Endocrinol. Invest. 22 (1999) 75-81
15. Thum T., Tsikas D., Frolich J.C., and Borlak J. Growth hormone induces eNOS expression and nitric oxide release in a cultured human endothelial cell line. FEBS Lett. 555 (2003) 567-571
16. Napoli R., Guardasole V., Angelini V., et al. Acute effects of growth hormone on vascular function in human subjects. J. Clin. Endocrinol. Metab. 88 (2003) 2817-2820
17. Thum T., and Bauersachs J. Growth hormone regulates vascular function-what we know from bench and bedside. Eur. J. Clin. Pharmacol. 62 Suppl. 1 (2006) 29-32
18. Teleron A.A., Carlson B., and Young P.P. Blood donor white blood cell reduction filters as a source of human peripheral blood-derived endothelial progenitor cells. Transfusion 45 (2005) 21-25
19. Sharpe III E.E., Teleron A.A., Li B., et al. The origin and in vivo significance of murine and human culture-expanded endothelial progenitor cells. Am. J. Pathol. 168 (2006) 1710-1721
20. Yoon C.H., Hur J., Park K.W., et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 112 (2005) 1618-1627
21. Dupont W.D., and Plummer Jr. W.D. Power and sample size calculations. A review and computer program. Control Clin. Trials 11 (1990) 116-128
22. Hur J., Yoon C.H., Kim H.S., et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 288-293
23. Young P.P., Vaughan D.E., and Hatzopoulos A.K. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog. Cardiovasc. Dis. 49 (2007) 421-429
24. Kawamoto A., Tkebuchava T., Yamaguchi J., et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 107 (2003) 461-468
25. Takahashi T., Kalka C., Masuda H., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5 (1999) 434-438
26. Kalka C., Masuda H., Takahashi T., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. USA 97 (2000) 3422-3427
27. Tepper O.M., Capla J.M., Galiano R.D., et al. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 105 (2005) 1068-1077
28. Rafii S., and Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9 (2003) 702-712
29. Schachinger V., Assmus B., Britten M.B., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J. Am. Coll. Cardiol. 44 (2004) 1690-1699
30. Rehman J., Li J., Orschell C.M., and March K.L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107 (2003) 1164-1169
31. Tsikas D., Gutzki F.M., and Stichtenoth D.O. Circulating and excretory nitrite and nitrate as indicators of nitric oxide synthesis in humans: methods of analysis. Eur. J. Clin. Pharmacol. 62 Suppl. 1 (2006) 51-59
32. Thum T., Hoeber S., Froese S., et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ. Res. 100 (2007) 434-443
33. Bahlmann F.H., de Groot K., Spandau J.M., et al. Erythropoietin regulates endothelial progenitor cells. Blood 103 (2004) 921-926
34. Bahlmann F.H., de Groot K., Mueller O., Hertel B., Haller H., and Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45 (2005) 526-529
35. Jorgensen J.O., Christensen J.J., Krag M., Fisker S., Ovesen P., and Christiansen J.S. Serum insulin-like growth factor I levels in growth hormone-deficient adults: influence of sex steroids. Horm. Res. 62 Suppl. 1 (2004) 73-76
36. Abdu T.A., Elhadd T.A., Buch H., Barton D., Neary R., and Clayton R.N. Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk. Clin. Endocrinol. (Oxf) 61 (2004) 387-393
37. Wideman L., Consitt L., Patrie J., et al. The impact of sex and exercise duration on growth hormone secretion. J. Appl. Physiol 101 (2006) 1641-1647
38. Lincoln D.T., Sinowatz F., Gabius S., et al. Subpopulations of stromal cells from long-term human bone marrow cultures: ontogeny of progenitor cells and expression of growth hormone receptors. Anat. Histol. Embryol. 26 (1997) 11-28
39. Hanley M.B., Napolitano L.A., and McCune J.M. Growth hormone-induced stimulation of multilineage human hematopoiesis. Stem Cells 23 (2005) 1170-1179
40. Hristov M., and Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J. Cell Mol. Med. 8 (2004) 498-508
41. Powell T.M., Paul J.D., Hill J.M., et al. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 296-301